Ocrelizumab (OCREVUS™), an anti-B cell therapy has been approved by the FDA as of March 28th 2017, for the treatment of Relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). This treatment is highly effective for RRMS, based on the data from the Phase III clinical studies. It is also the first drug approved for use in PPMS. At IMSMP/TISCH we have used Rituximab, a similar anti-B cell treatment, for the past 16 years with great success.
In observance of Memorial Day, the Center will be closing at 2 pm on Friday, May 26th, and will reopen on Tuesday, May 30th. We wish everyone a safe, healthy and happy holiday!
We are thrilled to announce, Dr. Saud A. Sadiq is a, New York Magazine, Best Doctor in the field of Neurology for 2017. Of the 40 neurologists selected for this prestigious recognition, Dr. Saud A. Sadiq is the only physician listed who specializes in multiple sclerosis.
To view Dr. Saud A. Sadiq's full bio, Click Here.
To view New York Magazine's Best Doctor's list, Click Here.